| AD | Alzheimer’s disease |
| ALS | Amyotrophic lateral sclerosis |
| Aβ | Amyloid β |
| BACE1 | Beta-site APP-cleaving enzyme 1 |
| BBB | Blood–brain barrier |
| CCH | Chronic cerebral hypofusion |
| CIS | Clinically isolated syndrome |
| CNS | Central nervous system |
| CSF | Cerebrospinal fluid |
| DS | Down syndrome |
| EBV | Epstein–Barr virus |
| EOAD | Early-onset Alzheimer’s disease |
| FLC | Immunoglobulin-free light chains |
| HLA | Human leukocyte antigen |
| KFLC | Kappa-free light chains |
| LFLC | Lambda-free light chains |
| LOAD | Late-onset Alzheimer’s disease |
| MCI | Mild cognitive impairment |
| miRNAs | microRNAs |
| MMPs | Matrix metalloproteinases |
| MS | Multiple sclerosis |
| NDs | Neurodegenerative diseases |
| Nf-L | Neurofilament light chains |
| NFTs | Neurofibrillary tangles |
| NF-κB | Nuclear factor κB |
| NGS | Next-generation deep sequencing |
| PD | Parkinson’s disease, |
| pNfH | Phosphorylated neurofilament heavy chains |
| PPMS | Primary progressive MS |
| pTau | Phosphorylated tau |
| pTau181 | Tau phosphorylated at threonine 181 |
| ROS | Reactive oxygen species |
| RRMS | Relapsing–remitting MS |
| SOD1 | Superoxide dismutase 1 |
| SPMS | Secondary progressive MS |
| TDP-43 | Transactive response DNA-binding protein 43 kDa |
| tTau | Total tau protein |